Hax1 regulates neutrophil adhesion and motility through RhoA

Peter J. Cavnar,1,2 Erwin Berthier,3,4 David J. Beebe,3,4 and Anna Huttenlocher1,2

1Department of Pediatrics, 2Department of Medical Microbiology and Immunology, 3Wisconsin Institutes for Medical Research, and 4Department of Biomedical Engineering, University of Wisconsin–Madison, Madison, WI 53706

Kostmann disease is an inherited severe congenital neutropenia syndrome associated with loss-of-function mutations in an adaptor protein HS1-associated protein X-1 (Hax1). How Hax1 regulates neutrophil function remains largely unknown. In this paper, we use ribonucleic acid interference to deplete Hax1 in the neutrophil-like cell line PLB-985 and identify Hax1 as a negative regulator of integrin-mediated adhesion and chemotaxis. Using microfluidics, we show that depletion of Hax1 impairs neutrophil uropod detachment and directed migration. Hax1-deficient cells also display increased integrin-mediated adhesion and reduced RhoA activity. Moreover, depletion of RhoA induces increased neutrophil adhesion and impaired migration, suggesting that Hax1 regulates neutrophil adhesion and chemotaxis through RhoA. Accordingly, activation of RhoA is sufficient to rescue adhesion of Hax1-deficient neutrophils. Together, our findings identify Hax1 as a novel regulator of neutrophil uropod detachment and chemotaxis through RhoA.

Results and discussion

Hax1 localizes to the leading edge during chemotaxis, and its expression is regulated by neutrophil differentiation

Hax1 is a ubiquitously expressed protein that directly interacts with HS1, Gα13, and β6 integrins. Depletion of endogenous Hax1 using siRNA impairs αvβ6 integrin–mediated migration of squamous cell carcinoma (Ramsay et al., 2007) and reduces migration of NIH3T3 cells (Radhika et al., 2004). However, no previous studies have addressed how Hax1 modulates neutrophil motility. Here, we characterize how Hax1 regulates neutrophil chemotaxis using small hairpin RNA (shRNA) depletion and live imaging with microfluidic RNA (shRNA) depletion and live imaging with microfluidic gradient generators. We identified a new role for Hax1 as a regulator of neutrophil uropod detachment and chemotaxis through the modulation of integrin-mediated adhesion and Rho GTPase signaling.
display increased neutrophil apoptosis in response to TNF-α or H2O2 (Klein et al., 2006). In the presence of H2O2, we observed a mild increase in the apoptosis of Hax1-deficient cells compared with control cells by annexin V staining, suggesting that Hax1 may modulate the sensitivity of PLB-985 cells to proapoptotic stimuli. However, there was no increase in the basal level of apoptosis (Fig. S1 A). Although Hax1 expression is regulated by neutrophil differentiation, we did not observe a defect in the differentiation of Hax1-depleted PLB-985 cells as indicated by normal surface expression of β2 integrin (Fig. S1 B).

To determine whether Hax1 is necessary for neutrophil chemotaxis, we performed time-lapse imaging of PLB-985 cells responding to a gradient of N-formyl-l-methionyl-l-leucyl-l-phenylalanine (fMLP) supplied from a micropipette tip. Hax1-deficient cells displayed impaired motility and an elongated uropod during chemotaxis on fibrinogen (Fig. 2, B and C; and Videos 4 and 5). Quantification of uropod length showed a greater than twofold increase in both Hax1-deficient cell lines compared with control (Fig. 2 C). The abnormal uropod morphology and detachment phenotype are similar to what has been reported with Rho inhibition (Alblas et al., 2001; Worthylake and Burridge, 2001; Yoshinaga-Ohara et al., 2002), suggesting that Hax1 may modulate rear retraction by regulating Rho GTPase signaling.

To determine whether Hax1 regulates Rho GTPase activation, RhoA activity assays were performed in control and Hax1-deficient cell lines. Using a pull-down assay, we found that RhoA activation was significantly decreased in Hax1-deficient PLB-985 cells stimulated with fMLP either in suspension (Fig. S1 C) or adherent to fibrinogen (Fig. 2 D). No significant difference in RhoA activity was detected in the absence of fMLP (unpublished data). Quantification of RhoA-GTP demonstrated in differentiated PLB-985 cells induced with DMSO compared with undifferentiated cells (Fig. 1 B). This is in contrast to vinculin, HS1, and actin, which were all increased upon differentiation. This finding suggests that Hax1 expression may play a role during neutrophil differentiation.

To characterize the intracellular distribution of Hax1 during neutrophil chemotaxis, we examined the subcellular localization of Hax1 in PLB-985 cells. We coexpressed Hax1-GFP and a marker of the neutrophil uropod that binds to stable F-actin, utrophin-RFP, in PLB-985 cells (Fig. 1 C and Videos 1, 2, and 3; Burkel et al., 2007; Cooper et al., 2008; Yoo et al., 2010). Live imaging demonstrated that Hax1-GFP predominantly localized to the leading edge, although rearward localization was also noted. To characterize the determinants of Hax1 localization, we generated truncation constructs lacking the C-terminal 166 amino acids necessary for binding HS1 and β13. Hax1 1–113–GFP no longer showed leading edge localization and concentrated in the middle of the cell body (Fig. 1 C and Video 2). In contrast, Hax1Δ113–GFP, which lacks the N-terminal 113 amino acids, was sufficient to localize to the leading edge of PLB-985 cells (Fig. 1 C and Video 3).

An attractive interacting partner that may mediate this targeting is the actin-binding protein HS1, which stabilizes actin branching at the leading edge (Uruno et al., 2003; Hao et al., 2005). Collectively, our findings identify Hax1 as a leading edge component that is differentially expressed during the differentiation of neutrophil-like PLB-985 cells.

Hax1 is necessary for neutrophil uropod detachment

To characterize Hax1 function, Hax1-deficient PLB-985 cells were generated using lentiviral-mediated shRNA (Fig. 2 A). Kostmann disease patients with loss-of-function Hax1 mutations display increased neutrophil apoptosis in response to TNF-α or H2O2 (Klein et al., 2006). In the presence of H2O2, we observed a mild increase in the apoptosis of Hax1-deficient cells compared with control cells by annexin V staining, suggesting that Hax1 may modulate the sensitivity of PLB-985 cells to proapoptotic stimuli. However, there was no increase in the basal level of apoptosis (Fig. S1 A). Although Hax1 expression is regulated by neutrophil differentiation, we did not observe a defect in the differentiation of Hax1-depleted PLB-985 cells as indicated by normal surface expression of αMβ2 integrin (Fig. S1 B).

To determine whether Hax1 is necessary for neutrophil chemotaxis, we performed time-lapse imaging of PLB-985 cells responding to a gradient of N-formyl-l-methionyl-l-leucyl-l-phenylalanine (fMLP) supplied from a micropipette tip. Hax1-deficient cells displayed impaired motility and an elongated uropod during chemotaxis on fibrinogen (Fig. 2, B and C; and Videos 4 and 5). Quantification of uropod length showed a greater than twofold increase in both Hax1-deficient cell lines compared with control (Fig. 2 C). The abnormal uropod morphology and detachment phenotype are similar to what has been reported with Rho inhibition (Alblas et al., 2001; Worthylake and Burridge, 2001; Yoshinaga-Ohara et al., 2002), suggesting that Hax1 may modulate rear retraction by regulating Rho GTPase signaling.

To determine whether Hax1 regulates Rho GTPase activation, RhoA activity assays were performed in control and Hax1-deficient cell lines. Using a pull-down assay, we found that RhoA activation was significantly decreased in Hax1-deficient PLB-985 cells stimulated with fMLP either in suspension (Fig. S1 C) or adherent to fibrinogen (Fig. 2 D). No significant difference in RhoA activity was detected in the absence of fMLP (unpublished data). Quantification of RhoA-GTP demonstrated in differentiated PLB-985 cells induced with DMSO compared with undifferentiated cells (Fig. 1 B). This is in contrast to vinculin, HS1, and actin, which were all increased upon differentiation. This finding suggests that Hax1 expression may play a role during neutrophil differentiation.
Localization of utrophin in neutrophils migrating in vivo (Yoo et al., 2010). We also found that Y-27632 impaired the uropod localization of utrophin-GFP (Fig. 2, E and F; and Video 6).

To determine whether Hax1 affects the uropod localization of utrophin, we expressed utrophin-GFP in control and Hax1-deficient cells and performed time-lapse imaging during neutrophil chemotaxis. The ratio of fluorescence intensity from the front of the cell to the rear showed a significant reduction of utrophin-GFP at the uropod of Hax1-deficient cells compared with control cells during chemotaxis (Fig. 2, E and F; and Video 7). Collectively, our findings suggest that a >10-fold reduction in RhoA activity in Hax1-deficient cells (Fig. 2 D). In contrast, Rac activation was increased approximately twofold in Hax1 knockdown cells (Fig. S1 D). Collectively, our findings indicate that Hax1 expression is necessary for optimal RhoA activity in neutrophils.

To determine whether Hax1 modulates the localized polarity of F-actin dynamics in motile neutrophils, we examined the localization of a probe for stable F-actin, utrophin-GFP, in control and Hax1-deficient PLB-985 cells. In previous experiments, we have reported that inhibition of the Rho-associated protein kinase with Y-27632 perturbs the uropod localization of utrophin in neutrophils migrating in vivo (Yoo et al., 2010). We also found that Y-27632 impaired the uropod localization of utrophin-GFP (Fig. 2, E and F; and Video 6).

To determine whether Hax1 affects the uropod localization of utrophin, we expressed utrophin-GFP in control and Hax1-deficient cells and performed time-lapse imaging during neutrophil chemotaxis. The ratio of fluorescence intensity from the front of the cell to the rear showed a significant reduction of utrophin-GFP at the uropod of Hax1-deficient cells compared with control cells during chemotaxis (Fig. 2, E and F; and Video 7). Collectively, our findings suggest that
Hax1 regulates the polarity of F-actin dynamics and rear detachment, likely through RhoA.

**Inhibition of integrin-mediated adhesion rescues chemotaxis of Hax1-deficient neutrophils**

To further characterize how Hax1 regulates neutrophil motility and uropod detachment, live imaging of control and Hax1-deficient cells was performed in microfluidic gradient generators. Static microfluidic gradient generation allows the precise control of chemoattractant gradients over extended durations under flow free conditions and can be used successfully to study neutrophil chemotaxis in a high throughput format (Abhyankar et al., 2008; Berthier et al., 2010). Hax1-deficient cells display impaired migration and develop elongated tails (arrowheads). Insets are zoomed regions indicated by the white squares. Bar, 100 µm. (C) Representative velocity and angle (insets) histogram of control and Hax1-deficient cells during chemotaxis on fibrinogen in the absence and presence of β2 or αvβ3 integrin function-blocking antibodies (from one of three independent experiments; n = 10 cells tracked over 30 min during chemotaxis). (D) Mean velocity heat map from three independent experiments in triplicate of control and Hax1 knockdown cells during chemotaxis on fibronectin (Fn), fibrinogen (Fbg), and vitronectin (Vn) and in the presence of integrin function-blocking antibodies on fibrinogen. n = 30 cells per replicate. ***, P < 0.01; t test.

Figure 3. Directed migration is impaired in Hax1-deficient PLB-985 cells using microfluidic gradient generators. (A) Schematic of the microfluidic device showing stable gradient formation with Alexa Fluor 488–conjugated dextran quantified by line scan analysis (yellow line). (B) Image from a time-lapse video showing the chemotactic behavior of control and Hax1 knockdown cells. (C) Representative velocity and angle (insets) histogram of control and Hax1-deficient cells during chemotaxis on fibrinogen in the absence and presence of β2 or αvβ3 integrin function-blocking antibodies (from one of three independent experiments; n = 10 cells tracked over 30 min during chemotaxis). (D) Mean velocity heat map from three independent experiments in triplicate of control and Hax1 knockdown cells during chemotaxis on fibronectin (Fn), fibrinogen (Fbg), and vitronectin (Vn) and in the presence of integrin function-blocking antibodies on fibrinogen. n = 30 cells per replicate. ***, P < 0.01; t test.
Hax1 and RhoA regulate neutrophil adhesion and motility

To determine whether Hax1 regulates global neutrophil adhesion, adhesion of control and Hax1-deficient cells was quantified on different ligands. Hax1-deficient PLB-985 cells treated with fMLP displayed a more than twofold increase in adhesion compared with control cells (Fig. 4 A), which was dependent on ligand density (Fig. S2, A and B). We did not observe differences in the surface expression of αβ3 integrin, total β2 integrin, or αMβ2 integrin (CD11b) in Hax1-deficient PLB-985 cells compared with control cells (Fig. S1 B and Fig. S2 C). To determine whether the increased adhesion observed in Hax1-deficient cells was mediated by cell surface integrins, we characterized the effects of β2 or αβ3 integrin function-blocking antibodies on the adhesion of control and Hax1 knockdown cells. Inhibition of either β2 or αβ3 integrins reduced the maximum adhesion observed (Fig. 4 B), whereas control IgG antibody had no effect (not depicted), indicating that the impaired migration was caused, at least in part, by increased integrin-mediated adhesion. Collectively, our findings demonstrate that Hax1 is necessary for efficient neutrophil chemotaxis on different integrin ligands by modulating uropod retraction.

Hax1 and RhoA regulate neutrophil adhesion and motility

To determine whether Hax1 regulates global neutrophil adhesion, adhesion of control and Hax1-deficient cells was quantified on different ligands. Hax1-deficient PLB-985 cells treated with fMLP displayed a more than twofold increase in adhesion compared with control cells (Fig. 4 A), which was dependent on ligand density (Fig. S2, A and B). We did not observe differences in the surface expression of αβ3 integrin, total β2 integrin, or αMβ2 integrin (CD11b) in Hax1-deficient PLB-985 cells compared with control cells (Fig. S1 B and Fig. S2 C). To determine whether the increased adhesion observed in Hax1-deficient cells was mediated by cell surface integrins, we characterized the effects of β2 or αβ3 integrin function-blocking antibodies on the adhesion of control and Hax1 knockdown cells. Inhibition of either β2 or αβ3 integrins reduced the maximum adhesion observed (Fig. 4 B), whereas control IgG antibody had no effect (not depicted).

To further investigate the relationship between Hax1 and RhoA in the regulation of neutrophil adhesion and motility, RNA interference was used to deplete RhoA from PLB-985 cells (Fig. 4 C). Similar to Hax1 depletion, RhoA-deficient neutrophils displayed a significant increase in adhesion to fibronectin (Fig. 4 D). Under steep gradients of fMLP using the needle assay, RhoA-deficient neutrophils exhibited impaired migration with multiple protrusions, similar to what has been previously reported (Video 10; Heasman et al., 2010). In microfluidic chambers that produce shallow chemoattractant gradients, RhoA knockdown cells showed impaired migration with elongated uropods and impaired detachment, similar to Hax1-deficient cells (Fig. 4 E and Fig. S2 D). Collectively, our
interacting partners that bind to the N-terminal 113 amino acids of Hax1.

Constitutively active RhoA rescues adhesion and partially rescues motility of Hax1-deficient neutrophils

To determine whether activation of RhoA is sufficient to rescue the adhesion and motility defects of Hax1-deficient neutrophils, we treated control and Hax1-depleted cells with nocodazole and colchicine or ectopically expressed constitutively active RhoA (Q63L). It has previously been reported that microtubule disruption with either nocodazole or colchicine increases global Rho activity in neutrophils (Niggli, 2003; Xu et al., 2005). Accordingly, we found that treatment with either nocodazole or colchicine rescued the adhesion defect of fMLP-treated Hax1-deficient cells to control levels (Fig. 5 B and Fig. S3 C). Moreover, findings demonstrate that Hax1 and RhoA regulate neutrophil chemotaxis through the modulation of integrin-mediated adhesion and uropod detachment.

The N-terminal region of Hax1 is sufficient to rescue neutrophil adhesion and motility of Hax1-deficient cells

We next sought to identify the regions of Hax1 that are sufficient to rescue the adhesion and motility defects of Hax1-deficient cells. Stable expression of shRNA-resistant full-length GFP-Hax1 (Fig. S3 A) was sufficient to rescue both neutrophil adhesion and chemotaxis (Fig. 5, A and D). Hax1-deficient PLB-985 cells stably expressing the N-terminal 113 amino acids of Hax1 (GFP–Hax1 1–113), but not the C-terminal 166 amino acids (GFP-Hax1Δ113), rescued neutrophil adhesion and motility (Fig. 5, A and D). Interestingly, there are currently no known interacting partners that bind to the N-terminal 113 amino acids of Hax1.

Constitutively active RhoA rescues adhesion and partially rescues motility of Hax1-deficient neutrophils

To determine whether activation of RhoA is sufficient to rescue the adhesion and motility defects of Hax1-deficient neutrophils, we treated control and Hax1-depleted cells with nocodazole and colchicine or ectopically expressed constitutively active RhoA (Q63L). It has previously been reported that microtubule disruption with either nocodazole or colchicine increases global Rho activity in neutrophils (Niggli, 2003; Xu et al., 2005). Accordingly, we found that treatment with either nocodazole or colchicine rescued the adhesion defect of fMLP-treated Hax1-deficient cells to control levels (Fig. 5 B and Fig. S3 C). Moreover,
stable expression of constitutively active GFP-RhoA (Q63L) (Fig. S3 B) in Hax1-deficient cells restored adhesion to control levels (Fig. 5 C). We did not observe any decrease in endogenous RhoA or Rac expression in PLB-985 cells that ectopically express constitutively active GFP-RhoA (Q63L) as has previously been reported for other cell types (Fig. S3 B; Boulter et al., 2010). Ectopic expression of constitutively active RhoA only partially rescued the migration defect of Hax1-deficient cells, suggesting that Hax1 may be necessary for optimum spatiotemporal regulation of RhoA during motility (Fig. 5 D). Collectively, our findings demonstrate that activation of RhoA is sufficient to rescue the adhesion defect of Hax1-deficient cells, indicating that Hax1 negatively regulates neutrophil adhesion through the modulation of RhoA activity.

In summary, we have identified Hax1 as a novel negative regulator of integrin-mediated adhesion that affects uropod detachment and neutrophil chemotaxis. We have also found that Hax1 regulates RhoA activation in neutrophils and that activation of RhoA is sufficient to rescue the adhesion defects of Hax1-deficient cells. Previous studies have suggested that Hax1 loss-of-function mutations mediate the development of congenital neutropenia syndromes through the regulation of neutrophil apoptosis (Klein et al., 2006; Chao et al., 2008). Our findings raise the intriguing alternative hypothesis that Hax1 deficiency may modulate neutrophil function by affecting Rho GTPase signaling and neutrophil adhesion and motility.

It is not clear how Hax1 regulates RhoA activity and neutrophil adhesion. Go13 and HS1 represent attractive candidates to mediate Hax1 effects. However, we found that the N-terminal region of Hax1, but not the region that interacts with Go13 and HS1, is sufficient to rescue neutrophil adhesion and motility. Accordingly, the C-terminal region of Hax1 localizes to the leading edge, whereas the N-terminal region of Hax1, which rescues uropod retraction, displays a more rearward localization. Furthermore, we found that ectopic expression of Hax1 uncovers constitutively active RhoA (Q63L) was sufficient to rescue the increased adhesion defect in Hax1-deficient cells. Interestingly, RhoA (Q63L) only partially rescued neutrophil motility, suggesting that the proper spatiotemporal regulation of RhoA is critical for efficient chemotaxis. To date, no binding partners have been identified that interact with the N-terminal region of Hax1. Understanding these types of interactions will likely shed light on how Hax1 functions to regulate rear detachment and neutrophil motility.

A final unanswered question is how Hax1 mutations affect neutrophil adhesion and motility to control neutrophil homeostasis in the context of congenital neutropenia syndromes. The finding that Hax1 expression is reduced with neutrophil differentiation is surprising. This raises the intriguing possibility that Hax1 expression has an important function during neutrophil differentiation and that its deficiency may allow the transition to the more adherent phenotype of mature neutrophils. Recent studies have shown that other congenital neutropenia syndromes, including WHIM (warts, hypogammaglobulinemia, infections, and myelokathexis) syndrome, have associated defects in neutrophil retention and motility (Kawai and Malech, 2009; Walters et al., 2010), suggesting that defects in neutrophil adhesion and migration may be key factors that contribute to the pathogenesis of other congenital neutropenia syndromes, such as Kostmann disease. A challenge for future studies will be to establish in vivo systems that will allow these kinds of questions to be answered.

Materials and methods

Antibodies and reagents

Sources for antibodies and reagents used in this study are mouse anti-Hax1 clone 52 and mouse anti-HS1 clone 9 (BD), rabbit anti-Hax1 (ProteinTech Group, Inc.), mouse antivinculin clone VIN-11-5 and mouse anti-β-actin clone AC-15 (Sigma-Aldrich), rabbit anti-RhoA (67B9) and rabbit anti–Rac1/2/3 (8129; Cell Signaling Technology), goat anti–rabbit Alexa Fluor 680 and goat anti–mouse Alexa Fluor 800 (Invitrogen), and mouse anti–αvβ3 integrin (clone LM609; Millipore), mouse anti–human CD18 (clone TS1/18), and mouse anti–human CD11b (clone CBRM1/5; BioLegend). Human fibrinogen, FMet-Leu-Phe (Sigma-Aldrich), nocardazole (EMD), colchicine (Arcos Organics), and fibronectin were purified from human plasma by affinity chromatography as previously described (Ruoslahti et al., 1982), and human vitronectin was a gift from D. Mosher (University of Wisconsin–Madison, Madison, WI).

Cell culture

PLB-985 cells (gift from C. Parent, National Cancer Institute, National Institutes of Health, Bethesda, MD) were maintained in RPMI 1,640 supplemented with 10% fetal bovine serum, 100 U/ml penicillin, and 100 µg/ml streptomycin at a concentration of 1.1–1.6 × 10^6 cells/ml. To differentiate, 1.25% DMSO was added to 2 × 10^6 cells/ml for 6 d. Differentiation was confirmed through FACS analysis of CD11b expression. HEK293T cells (American Type Culture Collection) and Platinum-GP cells (Cell Biolabs, Inc.) were maintained in Dulbecco’s minimal essential medium supplemented with 10% FBS, 100 U/ml penicillin, and 100 µg/ml streptomycin.

DNA constructs, transfections, and viral infections

Hax1 was RTPCR purified from TRIZOL-extracted total RNA from the neutrophil-like cell line HL-60 using the primers forward, 5′-ATAGGCG-TCTTIGACTTCTTCGGGGCTTTTGTCTC-3′, and reverse, 5′-CCGGGAG- GGAACCAACCTCCCCAGGAAATGAT-3′. Full-length Hax1, Hax1 1–113, and Hax1 Δ113 sequences were PCR amplified from Hax1 cDNA and cloned into pEGFP-N1 and pEGFP-C1 (Takara Bio Inc.). 2 × 10^6 PLB-985 cells 6 d after differentiation were transiently transfected with 5 µg DNA using a nucleofector [Cell Line Nucleofector Kit V; Lonza] following the manufacturer’s instructions.

Lentiviral Hax1 and RhoA shRNA targets were purchased from Thermofisher Scientific. Targets used in this study were Hax1 shRNA-A, 5′-ACAGACATCCGGACGCAACT-3′; Hax1 shRNA-B, 5′-CCAGGACGCGA TCTTACAGGT-3′; RhoA shRNA 1, 5′-GTACATGGAGGTTCAGCAAA-3′; RhoA shRNA 2, 5′-TGGAAGGACATGGCTGGTCACT-3′; and control shRNA, 5′-GTCTCGGACGTCGACAGGT-3′. HEK293T cells were grown to 70% confluency in a 10-cm tissue-culture dish for each lentiviral target and transfected using 6 µg Hax1 or RhoA shRNA, 0.6 µg VSVG, and 5.4 µg CMV 8.9.1. A 72-h viral supernatant was collected and concentrated using a lentivirus concentrator (Lenti-X, Takara Bio Inc.) following the manufacturer’s instructions. 10^8 PLB-985 cells were infected with viral supernatant for 3 d in the presence of 4 µg/ml polybrene. Stable cell lines were generated with 1 µg/ml puromycin selection.

Retroviral transduction of GFP-RhoA (Q63L) and shRNA-resistant GFP-Hax1, GFP-Hax1 1–113, and GFP-Hax1 Δ113 was performed as follows: Platinum-GP cells were grown to 70% confluency in a 10-cm tissue-culture dish and transfected using 10 µg retroviral DNA and 3 µg VSVG. A 72-h viral supernatant was collected and added to 10^9 PLB-985 cells for 3 d in the presence of 15 µg/ml polybrene. Cells were sorted for equal GFP expression levels using the cell sorter (FACSAria; BD) at the University of Wisconsin flow cytometry facility.

Needle chemotaxis

Stable cell lines expressing shRNA cell lines or transiently transfected cells expressing GFP or RFP fusion proteins were incubated in a 35-mm glass-bottom culture dish that had been coated with 10 µg/ml fibronectin and blocked with 2% BSA. 10^7 neutrophils were placed in Gey’s media (20 mM Hepes, 132 mM NaCl, 1 mM MgSO_4_, 1.2 mM NaH_2PO_4_, 5 mM glucose, 1 mM CaCl_2_, and 0.5% human serum albumin, American Red Cross Blood Services), and chemotaxis assays were performed using a microinjection.
system (FemtoJet; Eppendorf) as previously described (Servant et al., 1999; Lokuta et al., 2007). For some experiments, control shRNA cells were incubated with 30 nM Y27632 for 30 min before chemotaxis. Imaging was performed in a 37°C humidified chamber on an inverted microscope (Eclipse TE300; Nikon) using a 60x, NA of 1.4, or 10x, NA of 0.45, objective. Images were collected using a charge-coupled device camera (CoolSNAP ES²; Photometrics) and captured into MetaVue imaging software (v6.2; Molecular Devices).

Rho GTPase pull-down and immunoblotting

Rho GTPase pull-down assays were performed as previously described (Lokuta et al., 2003). In brief, differentiated PLB-985 cells were serum starved in modified HBSS (150 mM NaCl₂, 4 mM KCl, 1 mM MgCl₂, 10 mM glucose, 20 mM Hpes, pH 7.4, and 0.2% human serum albumin) and plated on 10 µg/ml fibronectin or kept in suspension for 10 min and then stimulated with 1 mM fMLP for 5 min, immediately placed on ice, and lysed in radioimmunoprecipitation assay extraction buffer (20 mM Tris-HCL, pH 7.5, 150 mM NaCl₂, 2 mM EDTA, 2 mM EGTA, 1% TX-100, 0.5% NP-40, 0.25% sodium deoxycholate, 1 µg/ml pepstatin A, 2 µg/ml aprotinin, 1 µg/ml leupeptin, and 200 µM phenylmethylsulfonyl fluoride). 40 µg of bate- rially expressed GST-rhotekin–Rho-binding domain (RBD) or GST-PAK–Rac/Cdc42 (p21)-binding domain (PBD) was incubated with the lysates for 1 h at 4°C. The affinity-precipitated products were run on an SDS-PAGE gel, transferred to nitrocellulose, and immunoblotted for RhoA or Rac. To detect endogenous Rac, we used a Rac1/2/3 antibody. Therefore, the PAK-PBD pull-down does not distinguish between Rac1 and Rac2. Quantification of total RhoA or Rac for all samples was normalized to control shRNA relative expression. The mean ± SEM ratio of RhoA-GTP/RhoA of total RhoA or Rac for all samples was normalized to control shRNA relative expression. In all assays, samples were run in duplicate and analyzed by phosphoimunoblotting by RhoGDI1.

For adhesion assays

100,000 Hax1-shRNA A, RhoA shRNA 1 and 2, or control shRNA cells were labeled with calcein AM (Invitrogen) and plated in the presence or absence of 200 nM fMLP in 30 min in quadruplicate in a 96-well black microplate (Greiner Bio-one) coated with fibrinogen, fibronectin, or vitronectin followed by blocking with 2% BSA. In some cases, cells were pre-treated with control IgG, β2, or αvβ3 (clone LM609) integrin-blocking antibodies at a concentration of 1:1,000 for 15 min at 4°C before plating. For microtubule disruption, cells were treated with 30 µM nocodazole or 10 µM colchicine for 30 min at 37°C. Fluorescence was measured using a plate reader (Victor® V; PerkinElmer). Plates were gently washed with modified HBSS in between readings until the remaining control shRNA/MLP cells were <10% of the original input.

Microfluidic chemotaxis assays

Microfluidic devices were fabricated as previously described (Berthier et al., 2010). In brief, the devices enable the generation of a static gradient of chemoattractant between a source chamber containing fMLP and a sink chamber containing the PLB-985 cells, which were connected by a 1-mm-long, 400-µm-wide thin channel in which the cells migrate. Microfluidic chambers were coated with fibronectin, fibronectin, or vitronectin for 1 h at room temperature in PBS. 3 µl neutrophil suspension (4 x 10⁶ cells/ml) was added to the device, and 100 nM fMLP was added to the source port. The gradient was allowed to set up and equilibrate in a 37°C humidified chamber for 15 min before imaging. Time-lapse imaging was performed using a 10x, NA of 0.45, objective and motorized stage (Ludl Electronic Products) on an inverted microscope (Eclipse TE300) using a charge-coupled device camera (CoolSNAP ES²) and captured into MetaVue imaging software v6.2. Images were taken every 30 s for 30–45 min with up to eight devices being imaged simultaneously. For integrin-blocking experiments, control IgG and β2 and αvβ3 integrin antibodies were incubated with cells at a concentration of 1:1,000 in ice for 30 min before loading in the microfluidic device. Tracking and velocity measurements were performed using ImageJ analysis software with the manual tracking plugin (National Institutes of Health).

Flow cytometry and apoptosis assay

For integrin αvβ3, integrin β2, and integrin αMβ2 surface staining of differentiated PLB-985 cells, 10⁶ cells were labeled with FITC-conjugated LM609, which binds to the αvβ3 complex, anti-CD18, or anti-CD11b for 30 min on ice. Cells were washed twice with FACS buffer (PBS supplemented with 2% FBS and 0.02% NaN₃) and analyzed by flow cytometry. For apoptosis induction of PLB-985 cells, 10⁵ 5-differentiated cells were incubated with 1 mM H₂O₂ for 30 min in PLB-985 media and then incubated in fresh media for 12 h. Cells were analyzed for apoptosis induction using the Annexin V Apoptosis Detection Kit I (BD) following the manufacturer’s instruction and analyzed by flow cytometry.

Statistical analysis

For statistical comparison, unpaired t test or one-way analysis of variance (ANOVA) was used with Tukey posttests with P < 0.05 considered significant.

Online supplemental material

Fig. S1 shows that Hax1-deficient PLB-985 cells have increased sensitivity to H₂O₂-induced apoptosis, reduced RhoA-GTP, and increased Rac-GTP levels. Fig. S2 shows that Hax1-deficient PLB-985 cells have increased adhesion to vitronectin and fibronectin, and RhoA-deficient cells display elongated uropods. Fig. S3 shows immunoblotting of Hax1-deficient PLB-985 cells expressing GFP-Hax1, Hax1 mutants, and constitutively active RhoA (Q63L). Video 1 shows Hax1-GFP localization in PLB-985 cells during chemotaxis. Video 2 shows Hax1–113–GFP localization in PLB-985 cells during chemotaxis. Video 3 shows Hax1Δ113–GFP localization in PLB-985 cells during chemotaxis. Video 4 shows the chemotaxis of control shRNA A–expressing PLB-985 cells. Video 5 shows the chemotaxis of Hax1 shRNA A–expressing PLB-985 cells. Video 6 shows utrophin-GFP localization in PLB-985 cells treated with Y27632 during chemotaxis. Video 7 shows utrophin-GFP localization in Hax1 shRNA A–expressing PLB-985 cells during chemotaxis. Video 8 shows control shRNA chemotaxis in microfluidic gradient generators. Video 9 shows Hax1 shRNA A in microfluidic gradient generators. Video 10 shows RhoA-deficient PLB-985 cells during chemotaxis. Online supplemental material is available at http://www.jcb.org/cgi/content/full/jcb.201010143/DC1.

We would like to thank Carole Parent and Deane Mosher for reagents. We thank Sarah Wernimont and Kathy Sell for their flow cytometry expertise. This work was supported by the National Institutes of Health grants R32E0027015 (to P.J. Cavnar) and GM074827 (to A. Huttenlocher), the American Heart Association grant 06POST3230031 (to P.J. Cavnar), and a Burroughs Wellcome grant (to A. Huttenlocher).

Submitted: 29 October 2010
Accepted: 29 March 2011

References


Downloaded from http://www.jcb.org on March 31, 2017


